TargetBeta
ROS1
ROS proto-oncogene 1, receptor tyrosine kinase · also MCF3, ROS, c-ros-1 · Fibronectin type III domain containing
8 programs in company-led studies act on ROS1, from 7 companies: 4 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 312 running | ALK, EML4, MET, MST1R, NPM1 | ChEMBL |
| taletrectinibrule | Nuvation Bio | phase 3 | 115 running | NTRK1, NTRK2, NTRK3 | NCIt |
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 93 running | ALK, CD74, NTRK1, NTRK2, NTRK3, PTK2, SDC4, SRC | NCIt |
| Fudotinibrule | Guangzhou JOYO Pharma | phase 3 | 33 running | – | NCIt |
| Cross-over to JYP0322rule | Guangzhou JOYO Pharma | phase 3 | 11 running | – | the studies' text |
| Radiosensitizer VS-101rule | VSPharmTech | phase 2 | 21 running | – | NCIt |
| ROS1/NTRK Inhibitor ANS03rule | Avistone Biotechnology | phase 1 | 11 running | – | NCIt |
| SIM0518rule | Simcere Pharmaceutical Group | phase 1 | 11 running | ALK | the studies' text |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 6 programs
- Lymphoma, 2 programs
- Neoplasms, 2 programs
- Glaucoma, Open-Angle, 1 program
- Lung Neoplasms, 1 program
- Lymphoma, Follicular, 1 program
- Lymphoma, Large-Cell, Anaplastic, 1 program
- Neoplasm Metastasis, 1 program
- Neoplasms, Squamous Cell, 1 program
- Sarcoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 2, 2027taletrectinib · Nuvation Bio · phase 3 · NCT07742384
- Feb 16, 2027repotrectinib · Bristol-Myers Squibb · phase 3 · NCT06140836
- Oct 31, 2027Fudotinib · Guangzhou JOYO Pharma · phase 3 · NCT07154368
- Oct 31, 2027Cross-over to JYP0322 · Guangzhou JOYO Pharma · phase 3 · NCT07154368
- Dec 2027Radiosensitizer VS-101 · VSPharmTech · phase 2 · NCT06959082
- Dec 30, 2027ROS1/NTRK Inhibitor ANS03 · Avistone Biotechnology · phase 1 · NCT06716138
- Mar 21, 2028Crizotinib · Pfizer · phase 4 · NCT05160922
- Dec 1, 2028SIM0518 · Simcere Pharmaceutical Group · phase 1 · NCT07912268
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.